0.49 (-%)
As of Feb 08, 2023
Source:
We are a clinical-stage biopharmaceutical company currently focused on discovering and developing differentiated therapies for patients with gastrointestinal, or GI, diseases. Our most advanced program, MET642, targets the farnesoid X receptor, or FXR, which is central to modulating GI and liver diseases. Prior to February 2022, we were developing another FXR agonist, MET409, for the treatment of non-alcoholic steatohepatitis, or NASH, a liver disease characterized by excess liver fat, inflammation and fibrosis.
Country | United States |
Headquarters | san diego, california |
Phone Number | 858-369-7800 |
Industry | manufacturing |
CEO | Preston Klassen |
Website | clinicaltrials.gov |